These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7488436)

  • 1. Active specific immunotherapy with an autologous virus-modified tumour cell vaccine in human renal cell carcinoma (RCC).
    Hinkel A; de Riese W; Alefelder J; Laumann D; Falkenberg FW; Senge T; Hertle L
    Eur J Cancer; 1995 Sep; 31A(10):1719-20. PubMed ID: 7488436
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized study of adjuvant immunotherapy with autologous tumor cells and BCG in renal cancer.
    Galligioni E; Francini M; Quaia M; Carbone A; Spada A; Sacco C; Favaro D; Santarosa M; Carmignani G; Di Donna D
    Ann N Y Acad Sci; 1993 Aug; 690():367-9. PubMed ID: 8368758
    [No Abstract]   [Full Text] [Related]  

  • 3. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma.
    Kugler A; Seseke F; Thelen P; Kallerhoff M; Müller GA; Stuhler G; Müller C; Ringert RH
    Br J Urol; 1998 Oct; 82(4):487-93. PubMed ID: 9806175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine.
    Repmann R; Wagner S; Richter A
    Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor cell vaccination for treatment of renal cell carcinoma].
    Kriegmair M; Oberneder R
    Urologe A; 1995 May; 34(3):204-7. PubMed ID: 7610513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.
    McCune CS; O'Donnell RW; Marquis DM; Sahasrabudhe DM
    Cancer Immunol Immunother; 1990; 32(1):62-6. PubMed ID: 2289200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy.
    Yoshimura K; Uemura H
    Int J Urol; 2013 Aug; 20(8):744-55. PubMed ID: 23521119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The present state and the future perspective of immunotherapy of renal cell carcinoma].
    Kawashima H
    Nihon Rinsho; 2015 Jan; 73(1):167-74. PubMed ID: 25626324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-modified immunotherapy for renal cell carcinoma.
    Kawai K; Tani K; Asano S; Akaza H
    Contrib Nephrol; 1999; 128():75-81. PubMed ID: 10597379
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects.
    Adler A; Gillon G; Lurie H; Shaham J; Loven D; Shachter Y; Shani A; Servadio C; Stein JA
    J Biol Response Mod; 1987 Dec; 6(6):610-24. PubMed ID: 3330126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
    Dillman RO; Beutel LD; Cornforth AN; Nayak SK
    Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
    Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V
    Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New trends in the diagnosis and treatment of renal cell carcinoma].
    Zisman A
    Harefuah; 2002 Aug; 141(8):713-7, 761. PubMed ID: 12222136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current modalities in immunotherapy of renal cell carcinoma].
    Aliaev IuG; Grigorian VA; Shpot' EV
    Ter Arkh; 2007; 79(6):78-82. PubMed ID: 17684975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.